ClinicalTrials.gg
Status unknownNCT05566353EMPSICOTUpdated May 28, 2024

Telemonitoring in Cochlear Implant Patient Care

An interventional study of Remote Check in Hearing Loss, sponsored by University Hospital, Montpellier. Status unknown at 1 site in France. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-28.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified May 2024), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

Following a sufficient delay after the cochlear implantation and initial implant activation, the patient will return to the hospital for follow-up visits for equipment maintenance and auditory performance evaluation only once per year. This frequency might appear either insufficient, in which case an additional patient check-up will be arranged, or excessive if patient performances and implant adjustments are stable. Using at-home testing tool for remote hearing performance monitoring can thus appear advantageous for both patients and clinicians, allowing to avoid an unnecessary journey to the implantation reference center for the first and to diminish a number of unscheduled medical appointments for the second.

Read the detailed description

In December 2020, the French Medical Device and Health Technology Evaluation Committee (CNEDiMTS) voted in favour of the integration of telemonitoring in cochlear implant users' follow-up thus adding a range of new possibilities to a standard health care routine.

According to the official recommendations of the French National Authority for Health, a patient implanted for a sufficiently long time should be seen annually at the implantation reference center. This periodicity might appear too low, in which case a patient will have to organise an unscheduled check-up appointment. Such appointments are a source of various problems: firstly, they disorganise the routine of the reference centers not adapted for emergency and semi-emergency situations; secondly, the patient might encounter substantial travelling fees (only 22 refence centers in France), especially if an implant component to replace is out of stock. Having an utility of remote patient monitoring is also beneficial in situations where the access to health care system is restricted, for example, the recent pandemic of Covid 19.

Cochlear™ has recently designed an at-home based patient testing tool, Remote Check application, permitting to complete a series of hearing test from a compatible smartphone. The results are then sent to the implantation reference center and evaluated by healthcare professionals. The data is securely stored on Cloud accessible to authorised clinicians via MyCochlear site.

Although the feasibility and the accuracy in detecting technical problems of remote follow-up of people with cochlear implant had been already assessed, its impact on health care system is still unknown. Hence, this project will be the first to evaluate an interest of implementing remote monitoring in following adults with cochlear implantation.

The main objective of the study is - to determine if the use of telemonitoring through Remote Check application reduces significantly a number of unscheduled check-up appointments in the reference centre during 1 year follow-up period for a patient with a cochlear implant Cochlear™ in comparison to traditional health care approach.

The secondary objectives are:

  • To compare a number of scheduled appointments during a period of Remote Check use versus a historical period of a traditional follow-up
  • To compare a number of indispensable unscheduled visits (unavoidable with or without Remote Check use) with a number of unnecessary ones (avoidable with Remote Check)
  • To measure the compliance of the Remote Check application use
  • To assess quantitatively and qualitatively a number of implant failures/dysfunctions identified with Remote Check
  • To evaluate for each study participant time spent by clinician to treat Remote Check analysis data uploaded to My Cochlear data base
  • To assess patients satisfaction of Remote Check implementation in their healthcare routine
  • To evaluate the quality of life specific to the Deaf before and after Remote Check use The study implies four visits for each patient. The inclusion visit (V0) is a routine check-up appointment in the implantation reference center. After the patient is informed and his/her consent is collected, the Remote Check application will be activated on his/her processor. Two next follow-up visits, V1 (V0+ 5 mois (± 0.5 mois)) and V2 (V0 + 11 mois (± 0.5 mois)), are remote visits with hearing test performed through Remote Check application. Final visit, V3 (V0 + 12 mois (± 0.5 mois)), corresponds to patient's annual check-up appointment. In case a problem with processor's functioning is detected during V2, it will be resolved at V3. Equipment verification will be also performed to detect failures missed by Remote Check.
02

Conditions studied

  • Hearing Loss

Browse trials for

Keywords

  • Remote monitoring
  • Cochlear implant
  • Telemedicine
  • Healthcare system
03

In context

Hearing Loss

1,109 studies on the registry are indexed under Hearing Loss; 233 are open to participants now.

This study's planned enrollment of 78 is above the median of 40 across 778 interventional studies indexed under Hearing Loss.

Browse Hearing Loss studies →

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,261 studies on the registry; 227 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects-users of uni- or bilateral cochlear implants (Cl24RE, series 400, 500 and 600) and Cochlear Nucleus processor CP1000 or CP1150 during one year minimum
  • Subjects who have already renewed their processor at least once
  • Subjects implanted for more than 5 years
  • Over 20 years old
  • Subjects with Apple or Android smartphones compatible with Remote Check

Exclusion criteria

Exclusion criteria:

  • Associated physical (visual, motor...) or severe cognitive (dementia, specific language development troubles) making impossible the use of smartphone software and the conduction of hearing tests
  • Patients unable to give oral informed consent
  • Patients residing in geographical zones with limited internet access
  • Subjects deprived of liberty by juridical or administrative decision
  • Patients subjected to legal protection measures (guardianship or curatorship)
  • Subjects for whom French is not a native language
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Patients followed at the implantation reference centers

    Patients eligible for implant processor renewal in 2 years and corresponding to inclusion criteria will be enrolled during their routine check-up appointment at the implantation reference centers of the University Hospitals of Montpellier and Toulouse. Patients will be their own controls through the use of their medical history data.

    Other: Remote Check

Interventions

  • OtherRemote Check

    Remote Check is a remote monitoring tool which permits patients with Cochlear Nucleus CP1000 or CP1150 processors to complete hearing tests (pure-tone and speech-in-voice audiometry, electrode impedance measures, implant functioning assessment) at home,

06

What researchers measure

Primary outcomes

  1. Patients with at least one unscheduled follow-up visit

    Annual percentage of patients-cochlear implant users having at least one unscheduled appointment at the reference center

    Time frame: 24 months from the start of the study

Secondary outcomes

  1. Scheduled and unscheduled visits during 1 year

    The number of scheduled and unscheduled (avoidable and unavoidable) visits during 1 year

    Time frame: 24 months from the start of the study

  2. Compliance measures

    The compliance will be measured by the number of Remote Check assessments in one year after the start of remote monitoring. Assessments performed within the timeframe and after the deadline will be identified.

    Time frame: 24 months from the start of the study

  3. Equipment failures and dysfunctions

    The number and the type of failures/dysfunctions identified by Remote Check

    Time frame: 24 months from the start of the study

  4. Time spent in MyCochlear for each patient

    Clinician login time spent on each subject's file on MyCochlear data base during the year of follow up

    Time frame: 24 months from the start of the study

  5. Patient satisfaction

    Patient satisfaction measured by the questionnaire validated in French language: "the Service User Technology Acceptability (SUTAQ)". Score will be assessed by 5 options from "Strongly disagree" (worse outcome), "Disagree somewhat", "Neither agree nor disagree", "agree somewhat" to "strongly agree" (better outcome)

    Time frame: 24 months from the start of the study

  6. Patient's Quality of Life

    Patient's quality of life score linked to deafness will be measured by the questionnaire Speech, Spatial and Qualities of Hearing scale (Sp-SSQ12) validated in french. Score will run from 0 (worse outcome) to 10 (better outcome)

    Time frame: 24 months from the start of the study

07

Study locations

1 of 1 sites recruiting
  • University Hospital Montpellier
    Montpellier, France
    • Frédéric Venail · Contact
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05566353
Collaborators
University Hospital, Toulouse, Groupement Interrégional de Recherche Clinique et d'Innovation, Foundation maladies rares, France, Cochlear
Responsible party
Sponsor
First posted
Oct 4, 2022
Start date
Dec 20, 2022
Primary completion
Jun 20, 2025 (estimated)
Completion
Jun 20, 2025 (estimated)
Last update
May 28, 2024

Study contacts

Frédéric Venail, PhD, MD
Contact
f-venail@chu-montpellier.fr
+33467336890
Olivier Deguine, PhD, MD
Contact
deguine.o@chu-toulouse.fr
+33561772211

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion